Who Paid My Doc
Tecartus
Drug Cellt
NDC 71287-219-02
General payments
$1,279,672
Research payments
$17,795,378
Through program year 2025, $1,279,672 in general payments and $17,795,378 in research payments were reported against Tecartus (Cellt).
No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.
By program year
12 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | General | $12,600 | 7 |
| 2025 | Research | $4,876,987 | 323 |
| 2024 | General | $41,828 | 40 |
| 2024 | Research | $2,785,423 | 222 |
| 2023 | General | $271,634 | 203 |
| 2023 | Research | $2,755,282 | 209 |
| 2022 | General | $347,215 | 217 |
| 2022 | Research | $2,879,522 | 183 |
| 2021 | General | $352,496 | 216 |
| 2021 | Research | $2,062,387 | 271 |
| 2020 | General | $253,900 | 132 |
| 2020 | Research | $2,435,777 | 126 |
Breakdown
Each share is of general payments naming this product in 2025.
Each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.
Each share is of general payments naming this product in 2025 where a state was reported.
Records
815 general · 1,334 researchEvery payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
What you are looking at
Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.